Here are the DEF 14A proxy statements from Treace Medical Concepts, Inc. (TMCI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TMCI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMCI filings page.
Treace Medical Concepts, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on May 19, 2026 at 11:00 a.m. Eastern Time. Stockholders will elect three Class II directors, approve on an advisory basis executive compensation, and ratify Grant Thornton LLP as independent auditor for 2026.
The Board recommends voting FOR all three proposals. The record date is March 23, 2026, covering 64,784,436 outstanding common shares. Treace highlights a bunion-focused portfolio now addressing all four bunion classes, with over 134,000 Lapiplasty patients treated since late 2015 and several new systems launched in 2025.
The company emphasizes a culture of integrity, a seven-member classified board with six independent directors, and human capital initiatives, including approximately 450 employees, internal promotions, low undesired turnover and high employee engagement relative to medical device and biotechnology peers.